Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma
Endocrine Oncology · 2023
DOI: 10.1530/eo-22-0040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Oncology, 2023. Verfasst von Sofia Maria Lider Burciulescu und 9 weiteren Autor:innen. Beteiligte Einrichtung: CI Parhon National Institute of Endocrinology, Bucharest, Romania. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Pheochromocytomas (PHEO) and paragangliomas (PGL) can occur sporadic or within genetic predisposition syndromes. Despite shared embryology, there are important differences between PHEO and PGL. The aim of this study was to describe the clinical presentation and disease characteristics of PHEO/PGL. A retrospective analysis of consecutively registered patients diagnosed with or treated for PHEO/PGL in a tertiary care centre was performed. Patients were compared according to anatomic location (PHEO vs PGL) and genetic status (sporadic vs hereditary). In total, we identified 38 women and 29 men, aged 50 ± 19 years. Of these, 42 (63%) had PHEO, and 25 (37%) had PGL. Patients with PHEO presented more frequently with sporadic than hereditary disease (45 years vs 27 (77%) vs 8 (23%)) than patients with PGL (9 (36%) vs 16 (64%), respectively) and were older at diagnosis (55 ± 17 vs 40 ± 18 years, P = 0.001), respectively). About half of the cases in both PHEO and PGL were diagnosed due to disease-related symptoms. In patients with PHEO, tumour diameter was larger ( P = 0.001), metanephrine levels higher ( P = 0.02), and there was more frequently a history of cardiovascular events than in patients with PGL. In conclusion, we found that patients with PGL more frequently have a hereditary predisposition than those with PHEO, contributing to the fact that diagnosis is generally made earlier in PGL. Although diagnosis in both PHEO and PGL was mostly due to related symptoms, patients with PHEO more often presented with cardiovascular comorbidities than those with PGL which might relate to a higher number of functionally active tumours in the former.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- CI Parhon National Institute of Endocrinology, Bucharest, Romania.
- Department of Thoracic and Vascular Surgery, Ghent University Hospital & Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, UGent, Ghent, Belgium.
- Department of Radiotherapy-Oncology, Ghent University Hospital, Ghent Belgium & Department of Human Structure and Repair, Faculty of Medicine and Health Sciences, UGent, Ghent, Belgium.
- Department of Head and Neck Surgery, Ghent University Hospital & Department of Head & Skin, Faculty of Medicine and Health Sciences, UGent, Ghent, Belgium.
- Department of Pathology, Ghent University Hospital, Ghent University & Department of Diagnostic Sciences, Faculty of Medicine and Health Sciences, UGent, Ghent, Belgium.
- Center for Medical Genetics, Ghent University Hospital & Department of Biomolecular Medicine, Faculty of Medicine and Health Sciences, UGent, Ghent, Belgium.
ORCID-Profile: Sofia Maria Lider Burciulescu, Robin de Putter, Bruno Lapauw
Zitieren
APA
Lider Burciulescu, S. M., Randon, C., Duprez, F., Huvenne, W., Creytens, D., Claes, K. B. M., de Putter, R., T'Sjoen, G., Badiu, C., & Lapauw, B. (2023). Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma. Endocrine Oncology. https://doi.org/10.1530/eo-22-0040
Vancouver
Lider Burciulescu SM, Randon C, Duprez F, Huvenne W, Creytens D, Claes KBM, et al. Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma. Endocrine Oncology. 2023. doi:10.1530/eo-22-0040
BibTeX
@article{LiderBurciulescu2023,
author = {Lider Burciulescu, Sofia Maria and Randon, Caren and Duprez, Frederic and Huvenne, Wouter and Creytens, David and Claes, Kathleen B M and de Putter, Robin and T'Sjoen, Guy and Badiu, Corin and Lapauw, Bruno},
title = {Clinical presentation of sporadic and hereditary pheochromocytoma/paraganglioma},
journal = {Endocrine Oncology},
year = {2023},
doi = {10.1530/eo-22-0040}
}
EUVIMED